Home » Newsletters » BioWorld Science

BioWorld Science

May 7, 2012

View Archived Issues

Otsuka Pharmaceutical reports new candidate cancer therapies

Novel inhibitors of diacylglycerol O-acyltransferase 1 presented

Abbott designs novel focal adhesion kinase 1 inhibitors

AstraZeneca scientists discover novel plasminogen inhibitors

New sodium channel antagonists described

Hepatitis C vaccine shows promise in proof-of-concept trial

BRISK PS trial compares brivanib to placebo in liver cancer

Phase II data presented on ACE-031 in boys with Duchenne's muscular dystrophy

Doxapram enantiomer retains respiratory stimulant properties without adverse effects

Novel multikinase inhibitor is active in FLT3-dependent leukemia cells

Isis begins phase II ISIS-APOCIIIRx study

Genfit reports on GFT-505 study in NAFLD/NASH

Gentium receives day 180 list from EMA for defibrotide MAA

Sato Pharmaceutical set to launch anesthetic cream in Japan

FDA approves expanded dose range for schizophrenia drug

Pfizer stops phase III study of Lyrica

Phase III study of hydroxychloroquine begins in Japan

Abbott to acquire melanocortin receptor agonist

MediGene receives final milestone payment for Eligard

Pfizer offers overview of first quarter 2012

Exelixis expands cabozantinib development program

Oncolytics Biotech enters into agreement for phase II Reolysin study

NIH launches program providing researchers access to industry compounds

Phase IIIb trial of Lyrica does not meet primary endpoint

Roche terminates development of antidyslipidemia drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.